Maintenance Combinatorial Myeloid Immunotherapy for Unresectable Pancreatic Cancer — Stella

Clinical trial discovery in plain English. Data sourced from ClinicalTrials.gov.

About Browse conditions ClinicalTrials.gov ↗

Stella is not a medical provider and does not give medical advice. AI-generated summaries are for informational purposes only. Always consult your doctor before making any healthcare decisions.

Maintenance Combinatorial Myeloid Immunotherapy for Unresectable Pancreatic Cancer — Stella

Home/Pancreatic Ductal Adenocarcinoma/

View on ClinicalTrials.gov

Recruiting

Back to Pancreatic Ductal Adenocarcinoma trials

Phase 2 — Testing in a larger group (up to a few hundred people) to further evaluate safety and begin to assess effectiveness.

Trial locations(1 site)

United States

Hospital of the University of Pennsylvania, Philadelphia, Pennsylvania

Key details

Phase

Safety & dosing

Sponsor

University of Pennsylvania

Collaborators

Lustgarten Foundation

Enrollment target

~100 participants

Started

November 2025

Primary completion

October 2027

Age range

18 Years and older

Last updated March 2026

Interested in joining?

Tell us you're interested and we'll help connect you with the research team. We'll never share your email without your permission.

Your name

Email address

Stella acts as an intermediary. Researcher contact info is never exposed.

Follow this trial

Get notified in plain English when this trial's status changes. No account required.